{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
glutathione disulfide
to a specific field?
Status:
US Approved Rx
(2011)
Source:
BLA125288
(2011)
Source URL:
First approved in 2011
Source:
BLA125288
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2025)
Source:
BLA761404
(2025)
Source URL:
First approved in 2010
Source:
BLA125320
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
BLA125472
(2013)
Source URL:
First approved in 2010
Source:
BLA125276
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
Source:
BLA125319
(2009)
Source URL:
First approved in 2009
Source:
BLA125319
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
Source:
BLA125326
(2009)
Source URL:
First approved in 2009
Source:
BLA125326
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2024)
Source:
BLA761425
(2024)
Source URL:
First approved in 2009
Source:
BLA125261
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
BLA125433
(2013)
Source URL:
First approved in 2009
Source:
BLA125289
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2008)
Source:
BLA125160
(2008)
Source URL:
First approved in 2008
Source:
BLA125160
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2007)
Source:
BLA125166
(2007)
Source URL:
First approved in 2007
Source:
BLA125166
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2007)
Source:
NDA022074
(2007)
Source URL:
First approved in 2007
Source:
NDA022074
Source URL:
Class:
PROTEIN
Conditions:
Lanreotide is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration on August 30, 2007. Lanreotide was developed in the lab of Dr. David H. Coy, School of Medicine. Dr. Coy serves as Director of the Peptide Laboratory. Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin. Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3, and 4. Activity at human SSTR 2 and 5 is the primary mechanism believed responsible for GH inhibition. Like somatostatin, lanreotide is an inhibitor of various endocrine, neuroendocrine, exocrine and paracrine functions. Lanreotide inhibits the basal secretion of motilin, gastric inhibitory peptide and pancreatic polypeptide, but has no significant effect on the secretion of secretin. Lanreotide inhibits postprandial secretion of pancreatic polypeptide, gastrin and cholecystokinin (CCK). In healthy subjects, lanreotide produces a reduction and a delay in post-prandial insulin secretion, resulting in transient, mild glucose intolerance.
